FMP

FMP

Enter

MRNA - Moderna, Inc.

photo-url-https://images.financialmodelingprep.com/symbol/MRNA.png

Moderna, Inc.

MRNA

NASDAQ

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

54.45 USD

-0.775 (-1.42%)

About

ceo

Mr. Stephane Bancel

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; ca...

CIK

0001682852

ISIN

US60770K1079

CUSIP

60770K107

Address

200 Technology Square

Phone

617 714 6500

Country

US

Employee

5,600

IPO Date

Dec 7, 2018

MRNA Financial Summary

CIK

0001682852

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

60770K107

ISIN

US60770K1079

Country

US

Price

54.45

Beta

1.66

Volume Avg.

5.14M

Market Cap

20.93B

Shares

-

52-Week

52.26-170.47

DCF

-78.68

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-3.55

P/B

-

Website

https://www.modernatx.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest MRNA News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep